Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Comorbidities, concomitant medications and potential drug‐drug interactions with interferon‐free direct‐acting antiviral agents in hepatitis C patients in Taiwan
Chen‐Hua Liu, Ming‐Lung Yu, Cheng‐Yuan Peng, et al.
Alimentary Pharmacology & Therapeutics (2018) Vol. 48, Iss. 11-12, pp. 1290-1300
Open Access | Times Cited: 49

Showing 1-25 of 49 citing articles:

2020 Taiwan consensus statement on the management of hepatitis C: Part (II) special populations
Ming‐Lung Yu, Pei‐Jer Chen, Chia‐Yen Dai, et al.
Journal of the Formosan Medical Association (2020) Vol. 119, Iss. 7, pp. 1135-1157
Open Access | Times Cited: 86
Evolution of eGFR in chronic HCV patients receiving sofosbuvir-based or sofosbuvir-free direct-acting antivirals
Chen‐Hua Liu, Mei–Hsuan Lee, Jou‐Wei Lin, et al.
Journal of Hepatology (2019) Vol. 72, Iss. 5, pp. 839-846
Closed Access | Times Cited: 53
Sofosbuvir/velpatasvir with or without low-dose ribavirin for patients with chronic hepatitis C virus infection and severe renal impairment
Chen‐Hua Liu, Chi-Yi Chen, Wei‐Wen Su, et al.
Gut (2021) Vol. 71, Iss. 1, pp. 176-184
Closed Access | Times Cited: 35
Sofosbuvir/velpatasvir/voxilaprevir for patients with chronic hepatitis C virus infection previously treated with NS5A direct-acting antivirals: a real-world multicenter cohort in Taiwan
Chen‐Hua Liu, Cheng‐Yuan Peng, Chun‐Jen Liu, et al.
Hepatology International (2023) Vol. 17, Iss. 2, pp. 291-302
Open Access | Times Cited: 16
Cutting-edge pharmacotherapy for hepatitis C virus infection: a comprehensive review
Chen‐Hua Liu, Yu‐Ping Chang, Jia‐Horng Kao
Expert Opinion on Pharmacotherapy (2024) Vol. 25, Iss. 12, pp. 1691-1706
Closed Access | Times Cited: 5
Prescription patterns of comedications associated with drug-drug interactions risk in HCV-infected patients undergoing direct-acting antiviral treatment: an analysis of an administrative claims database in Japan
Daisuke Nakamoto, Yi Piao, Hajime Mizutani, et al.
Journal of Pharmaceutical Health Care and Sciences (2025) Vol. 11, Iss. 1
Open Access
HCV reinfections after viral clearance among HIV‐positive patients with recent HCV infection in Taiwan
Miao‐Hui Huang, Sui‐Yuan Chang, Chen‐Hua Liu, et al.
Liver International (2019) Vol. 39, Iss. 10, pp. 1860-1867
Closed Access | Times Cited: 30
Sofosbuvir/velpatasvir for patients with chronic hepatitis C virus infection and compensated liver disease: real-world data in Taiwan
Chen‐Hua Liu, Po-Yueh Chen, Jyh-Jou Chen, et al.
Hepatology International (2021) Vol. 15, Iss. 2, pp. 338-349
Open Access | Times Cited: 25
Glecaprevir/pibrentasvir for patients with chronic hepatitis C virus infection and severe renal impairment
Chen‐Hua Liu, Sheng‐Shun Yang, Cheng‐Yuan Peng, et al.
Journal of Viral Hepatitis (2020) Vol. 27, Iss. 6, pp. 568-575
Closed Access | Times Cited: 25
Pan-genotypic direct-acting antivirals for patients with hepatitis C virus infection and chronic kidney disease stage 4 or 5
Chen‐Hua Liu, Jia‐Horng Kao
Hepatology International (2022) Vol. 16, Iss. 5, pp. 1001-1019
Open Access | Times Cited: 14
HCV-infected individuals have higher prevalence of comorbidity and multimorbidity: a retrospective cohort study
Curtis Cooper, Chrissi Galanakis, Jessy Donelle, et al.
BMC Infectious Diseases (2019) Vol. 19, Iss. 1
Open Access | Times Cited: 21
Hepatitis C Virus Infection and Hospital-Related Outcomes: A Systematic Review
Michelle Ng, Patrizia Carrieri, Lindila Awendila, et al.
Canadian Journal of Gastroenterology and Hepatology (2024) Vol. 2024, pp. 1-23
Open Access | Times Cited: 2
Sofosbuvir‐based direct acting antiviral therapies for patients with hepatitis C virus genotype 2 infection
Chen‐Hua Liu, Tung‐Hung Su, Chun‐Jen Liu, et al.
Journal of Gastroenterology and Hepatology (2019) Vol. 34, Iss. 9, pp. 1620-1625
Closed Access | Times Cited: 18
Sofosbuvir/velpatasvir plus ribavirin for Child-Pugh B and Child-Pugh C hepatitis C virus-related cirrhosis
Chen‐Hua Liu, Chi-Yi Chen, Wei‐Wen Su, et al.
Clinical and Molecular Hepatology (2021) Vol. 27, Iss. 4, pp. 575-588
Open Access | Times Cited: 15
Outreach onsite treatment with a simplified pangenotypic direct-acting anti-viral regimen for hepatitis C virus micro-elimination in a prison
Chun‐Ting Chen, Ming‐Ying Lu, Meng‐Hsuan Hsieh, et al.
World Journal of Gastroenterology (2022) Vol. 28, Iss. 2, pp. 263-274
Open Access | Times Cited: 11
Comedications and potential drug-drug interactions with direct-acting antivirals in hepatitis C patients on hemodialysis
Po‐Yao Hsu, Yu‐Ju Wei, Jia‐Jung Lee, et al.
Clinical and Molecular Hepatology (2020) Vol. 27, Iss. 1, pp. 186-196
Open Access | Times Cited: 15
Sofosbuvir–velpatasvir in adults with hepatitis C virus infection and compensated cirrhosis in Japan
Tetsuo Takehara, Namiki Izumi, Satoshi Mochida, et al.
Hepatology Research (2022) Vol. 52, Iss. 10, pp. 833-840
Open Access | Times Cited: 9
TASL, TADE, and DAROC consensus for the screening and management of hepatitis C in patients with diabetes
Ming‐Lung Yu, Chih‐Yuan Wang, Mei–Hsuan Lee, et al.
Journal of the Formosan Medical Association (2023) Vol. 122, Iss. 3, pp. 202-220
Open Access | Times Cited: 5
Efficacy and safety of sofosbuvir–velpatasvir and sofosbuvir–velpatasvir–voxilaprevir for hepatitis C in Korea: a Phase 3b study
Jeong Heo, Yoon Jun Kim, Sung Wook Lee, et al.
The Korean Journal of Internal Medicine (2023) Vol. 38, Iss. 4, pp. 504-513
Open Access | Times Cited: 5
Real-world effectiveness and safety of sofosbuvir and ledipasvir with or without ribavirin for patients with hepatitis C virus genotype 1 infection in Taiwan
Chen‐Hua Liu, Chun‐Jen Liu, Tung‐Hung Su, et al.
PLoS ONE (2018) Vol. 13, Iss. 12, pp. e0209299-e0209299
Open Access | Times Cited: 14
Real-world safety and efficacy of paritaprevir/ritonavir/ombitasvir plus dasabuvir ± ribavirin in patients with hepatitis C virus genotype 1 and advanced hepatic fibrosis or compensated cirrhosis: a multicenter pooled analysis
Chun‐Hsien Chen, Chien‐Hung Chen, Chih‐Lang Lin, et al.
Scientific Reports (2019) Vol. 9, Iss. 1
Open Access | Times Cited: 11
Elbasvir/grazoprevir for hepatitis C virus genotype 1b East-Asian patients receiving hemodialysis
Chen‐Hua Liu, Cheng‐Yuan Peng, Yu‐Jen Fang, et al.
Scientific Reports (2020) Vol. 10, Iss. 1
Open Access | Times Cited: 11
Drug-drug interactions between antithrombotics and direct-acting antivirals in hepatitis C virus (HCV) patients: A brief, updated report
Mario Enrico Canonico, Giuseppe D. Sanna, Roberta Siciliano, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 6
Paritaprevir/ritonavir, ombitasvir plus dasabuvir for East Asian non‐cirrhotic hepatitis C virus genotype 1b patients receiving hemodialysis
Chen‐Hua Liu, Yu‐Lueng Shih, Sheng‐Shun Yang, et al.
Journal of Gastroenterology and Hepatology (2019) Vol. 34, Iss. 11, pp. 1977-1983
Closed Access | Times Cited: 8
Comparison of 8- versus 12-weeks of glecaprevir/pibrentasvir for Taiwanese patients with hepatitis C and compensated cirrhosis in a real-world setting
Yung-Hsin Lu, Chung‐Kuang Lu, Chun-Hsien Chen, et al.
PLoS ONE (2022) Vol. 17, Iss. 8, pp. e0272567-e0272567
Open Access | Times Cited: 5
Page 1 - Next Page

Scroll to top